CHGC
Research type
Research Study
Full title
Culture of human glioma cells freshly excised from tumour samples for in vitro and in vivo studies.
IRAS ID
354577
Contact name
Khuloud Al-Jamal
Contact email
Sponsor organisation
King’s College London
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Gliomas are among the most common types of primary brain tumours, accounting for about 80-85% of all malignant brain tumours. These tumours originate from glial cells in the central nervous system, with prognosis highly dependent on the tumour grade and the specific glial cell type invovled. Glioblastomas, a grade IV glioma, are the most aggressive form, with a 5-year survival rate of only 5–10%. Currently, treatment options for glioblastoma include surgery, radiotherapy and chemotherapy. However, these treatments are often insufficient for the complete resection of glioma and more aggressive relapses are common. Our research aims to develop a novel combinatory immunotherapy for glioblastoma by enhancing immune responses through a co-delivery system, evaluating its efficacy in patient-derived cells and relevant models.
REC name
North of Scotland Research Ethics Committee 1
REC reference
25/NS/0054
Date of REC Opinion
16 May 2025
REC opinion
Favourable Opinion